Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 11.63M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -95.06M | Forward P/E | -0.59 | EPS next Y | - | 50D Avg Chg | -24.00% |
| Sales | 25.77M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -75.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 3.00 | Quick Ratio | 0.20 | Shares Outstanding | 73.33M | 52W Low Chg | 1,222.00% |
| Insider Own | 52.70% | ROA | -60.99% | Shares Float | 24.80M | Beta | 0.99 |
| Inst Own | 29.38% | ROE | - | Shares Shorted/Prior | 514.98K/510.79K | Price | 0.16 |
| Gross Margin | -6.95% | Profit Margin | -216.48% | Avg. Volume | 533,209 | Target Price | 0.45 |
| Oper. Margin | -472.72% | Earnings Date | Aug 14 | Volume | 185,167 | Change | 0.00% |
About Gelesis Holdings, Inc.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.